Drug intelligence / Profile preview

Revitaderm40

Development stage
Unknown
Lead developer
Blaine Pharmaceuticals
Modality
Small Molecules
Administration
Topical
01

Overview

Revitaderm40 is a topical keratolytic emollient cream developed by Blaine Labs, containing 40% urea as its primary active ingredient. It is designed to treat conditions characterized by thickened or dry skin, such as xerosis, hyperkeratosis, and calluses. Urea acts as a humectant, increasing water retention in the stratum corneum, and as a keratolytic agent, which softens and dissolves the intercellular matrix of the keratinized epithelium. This dual action promotes the exfoliation of dead skin cells and restores the skin's moisture barrier. The formulation often includes supportive botanical ingredients like aloe vera, tea tree oil, and chamomile to soothe the skin. It is particularly marketed for podiatric use, including intensive diabetic foot care.

Brand names
Revitaderm40Revitaderm-40Revitaderm 40Revitaderm40 Advanced Skin CreamRevitaderm-40 Advanced Skin CreamRevitaderm 40 Advanced Skin Cream
Other names
Revitaderm 40Revitaderm40Revitaderm-40urea cream

Beyond the preview

Go deeper on Revitaderm40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revitaderm40.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call